Merrimack Pharmaceuticals, Inc.
MACK
MACK was delisted on the 17th of May, 2024.
63 hedge funds and large institutions have $33.6M invested in Merrimack Pharmaceuticals, Inc. in 2018 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 18 increasing their positions, 20 reducing their positions, and 15 closing their positions.
7% more capital invested
Capital invested by funds: $31.4M → $33.6M (+$2.29M)
10% less repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 20
16% less call options, than puts
Call options by funds: $195K | Put options by funds: $233K
17% less funds holding
Funds holding: 76 → 63 (-13)
80% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 15
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CC
Clearline Capital
New York
|
+$1.4M |
| 2 |
Dimensional Fund Advisors
Austin,
Texas
|
+$563K |
| 3 |
RCMNY
Rubric Capital Management (New York)
New York
|
+$419K |
| 4 |
Two Sigma Investments
New York
|
+$303K |
| 5 |
JP Morgan Chase
New York
|
+$295K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Russell Investments Group
London,
United Kingdom
|
-$543K |
| 2 |
Goldman Sachs
New York
|
-$340K |
| 3 |
PP
Paloma Partners
Greenwich,
Connecticut
|
-$307K |
| 4 |
Morgan Stanley
New York
|
-$265K |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
-$259K |
MACK Hedge Fund Activity: Q3 2018 in Review
63 of the 4,391 institutional investors tracked by Wall St. Rank reported a position in Merrimack Pharmaceuticals, Inc. (MACK) for Q3 2018, worth a combined $33.6M — up 7.3% from $31.4M a quarter earlier.
Sellers outnumbered buyers: 15 funds closed out of MACK and 3 opened new positions — a net loss of 12 holders — while 20 trimmed existing stakes and 18 added.
The largest buyer was Clearline Capital, adding an estimated $1.4M. The largest seller was Russell Investments Group, cutting an estimated $543K.
- 63 institutional investors held Merrimack Pharmaceuticals, Inc. (MACK) as of Q3 2018, down from 76 in Q2 2018.
- Funds reported $33.6M of Merrimack Pharmaceuticals, Inc. stock for Q3 2018, up 7.3% quarter-over-quarter.
- 3 funds opened new Merrimack Pharmaceuticals, Inc. positions in Q3 2018 and 15 closed out, a net change of -12 holders.
- The largest Merrimack Pharmaceuticals, Inc. buyer in Q3 2018 was Clearline Capital, an estimated $1.4M added.
- The largest Merrimack Pharmaceuticals, Inc. seller in Q3 2018 was Russell Investments Group, an estimated $543K sold.
Based on aggregated 13F filings for Q3 2018.